Galvanize Therapeutics Raises $130 Million in Series D Funding
On November 16, 2026, Galvanize Therapeutics, a pioneering company in pulsed electric field (PEF) ablation technologies for oncology and chronic diseases, announced a significant achievement: the successful closing of an oversubscribed Series D financing round amounting to $130 million. This funding aims to support the company's ongoing commercial expansion and the advancement of its innovative PEF technology, specifically its Aliya system.
The financing round was spearheaded by HealthQuest Capital, a growth equity firm focused on bolstering commercial-stage healthcare companies. Joining HealthQuest as new investors were Olympus Innovation Ventures and Braidwell LP, alongside participation from existing investors such as Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, and several others.
In the past year, Galvanize has demonstrated considerable momentum in commercial and clinical advancements. Noteworthy milestones include obtaining FDA clearance and successfully launching the next-generation Aliya EX Generator. With over 4,000 procedures performed using the Aliya technology, the company's efforts have been met with growing physician adoption. Additionally, Galvanize has placed emphasis on strengthening its clinical evidence program, having enrolled more than 300 patients in its PROPEL registry and contributing significantly to scientific research with over 40 peer-reviewed publications that explore the mechanisms and applications of PEF in oncology and chronic disease management.
Doug Godshall, Chairman and CEO of Galvanize Therapeutics, highlighted the significance of this financing, stating, "This financing marks an important inflection point for Galvanize... We're grateful for the continued confidence of our investors as we enter this next phase of growth." The funds raised through this financing will be allocated towards further commercial expansion of the Aliya platform, enhancement of clinical evidence production, progression of RheOx therapy for chronic bronchitis, and the development of next-generation PEF technologies and platforms.
Garheng Kong, MD, PhD, Founder and Managing Partner of HealthQuest Capital, expressed enthusiasm for their investment, stating, "Galvanize has built a differentiated PEF platform with the potential to meaningfully advance care in interventional oncology and pulmonology..." He will also join the Board of Directors of Galvanize.
About the Aliya PEF System
The Aliya EX is an advanced generator designed for the Aliya PEF System, which utilizes high-voltage, short-duration electrical energy to induce non-thermal regulated cell death during soft tissue surgeries. Preliminary research suggests that Aliya PEF could enhance immune responses, although further studies are necessary to establish the effectiveness of the Aliya system in generating patient benefits.
About Galvanize Therapeutics
Headquartered in Redwood City, California, Galvanize Therapeutics is at the forefront of pulsed electric field technologies aimed at leveraging biological processes for applications in oncology and lung diseases. While its Aliya PEF platform is being commercialized in the United States, the company is also working on an expanding pipeline of innovative technologies across various medical fields. More information can be found on their website:
www.galvanizetx.com.
About HealthQuest Capital
HealthQuest Capital is a private investment firm dedicated to providing capital to transformative healthcare companies, focusing on improving patient outcomes and healthcare delivery efficiency. With around $2 billion in committed capital, their portfolio encompasses a diverse array of medical technologies, diagnostics, digital health, and innovative services.
Overall, Galvanize Therapeutics’ latest funding round signifies a pivotal moment in the company's trajectory towards innovation and expansion in the healthcare sector, particularly in the realms of oncology and chronic disease therapeutics.